

Claim Rejections - 35 U.S.C. § 102

Claims 20-21 are rejected by the Examiner under 35 U.S.C. § 102 as being anticipated by Lindberg et al. as evidenced by Petterson. Applicants have amended claims 20 and 21 to be directed to a method for treating leukemia comprising administering to a person in need there of an effective amount of a monoclonal antibody or a fragment thereof that specifically recognizes and binds to an Integrin Associated Protein (IAP). The present claims, as amended, are not anticipated by Lindberg et al. because Lindberg et al. fails to disclose a method for treating leukemia. Therefore, Applicants respectfully request reconsideration and withdrawal of the rejection.

Claim Rejections - 35 U.S.C. § 103

Claims 15-16, 18 and 20-21 are rejected by the Examiner under 35 U.S.C. § 103 as being unpatentable over Lindberg et al. as evidenced by Petterson and further in view of Goding. Applicants have amended claims 20 and 21 to be directed to a method for treating leukemia comprising administering to a person in need there of an effective amount of a monoclonal antibody or a fragment thereof that specifically recognizes and binds to an Integrin Associated Protein (IAP). The present claims, as amended, are not obvious over Lindberg et al. in view of Goding because Lindberg et al. fails to disclose a method for treating leukemia and Goding fails to cure the deficiencies of Lindberg et al. Therefore, Applicants respectfully request reconsideration and withdrawal of the rejection.

Claim Rejections - 35 U.S.C. § 112, First Paragraph

Claims 13-14 and 17 are rejected by the Examiner under 35 U.S.C. § 112, first paragraph, for lack of written description. Applicants have canceled claims 13-14 and 17. Therefore, the present rejection is moot.

CONCLUSION

As the above-presented amendments and remarks address and overcome all of the rejections presented by the Examiner, withdrawal of the rejections and allowance of the claims are respectfully requested.

If the Examiner has any questions concerning this application, he or she is requested to contact the undersigned.

Respectfully submitted,

Date Dec. 11, 2002

By Eve L. Frank

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

Eve L. Frank
Registration No. 46,785

6142

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No. 19-0741 for any such fees; and applicant(s) hereby petition for any needed extension of time.

VERSION WITH MARKINGS TO SHOW CHANGES MADE

20. (2X Amended) A method for treating leukemia [An antileukemic agent,] comprising administering to a person in need there of an effective amount of a monoclonal antibody or a fragment thereof that specifically recognizes and binds to an Integrin Associated Protein (IAP)[, wherein said binding of said monoclonal antibody or said fragment thereof induces apoptosis of nucleated blood cells].

21. (Amended) The [antileukemic agent] method according to claim 20, wherein [the] said IAP is of human origin.